Takeda R&D head: Drugmaker may not be a frontrunner, and that’s OK

After executing one of the drug industry’s biggest acquisitions in recent years, it would be easy to assume that Takeda Pharmaceutical Co. Ltd. executives would paint the company as a frontrunner. But that’s not entirely the case.